Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMO381I)

• Drug Name: Acamprosate Drug Info
• Synonyms: AOTA; Acamprosato; Acamprosatum; Acamprostate; Aotal; Campral; Calcium acetyl homotaurinate; Calcium acetylhomotaurinate; Calcium acetylhomotaurine; Sodium acetylhomotaurine; Acamprosate 6473; Acamprosate (Campral); Acamprosate (INN); Acamprosate [INN:BAN]; Acamprosato [INN-Spanish]; Acamprosatum [INN-Latin]; Aotal (TN); Campral (TN); N-Acetylhomotaurine; 3-(Acetylamino)propanesulphonic acid; 3-Acetamido-1-propanesulfonic acid; 3-acetamidopropane-1-sulfonic acid

Indication

Disease Entry	ICD 11	Status	REF
Alcohol dependence	6C40.2	Approved	[1]

• Therapeutic Class: Alcohol Deterrents
• Cross-matching ID:
  PubChem CID: 71158
  ChEBI ID: CHEBI:51041
  CAS Number: CAS 77337-76-9
  TTD Drug ID: DMO381I
  ACDINA Drug ID: D00006

Molecule-Related Drug Atlas

Drug(s) Targeting Glutamate receptor AMPA (GRIA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Halothane	DM80OZ5	Anaesthesia	9A78.6	Approved	[3]
E-2007	DMJDYNQ	Diabetic neuropathy	8C0Z	Approved	[4]
Zopiclone	DMPI6Z0	Insomnia	7A00-7A0Z	Approved	[5]
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[6]
Enflurane	DM0YJSB	Anaesthesia	9A78.6	Approved	[7]
Isoflurane	DMY6T31	Anaesthesia	9A78.6	Approved	[8]
Bromazepam	DMY9TCW	Anxiety disorder	6B00-6B0Z	Approved	[9]
Artemisinin SP	DMFETDK	Malaria	1F40-1F45	Approved	[10]
Dihydroergotoxine	DM5D6WZ	Alzheimer disease	8A20	Approved	[11]
Barbiturate	DMJIA6T	Anaesthesia	9A78.6	Approved	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glutamate receptor AMPA (GRIA)	TTAN6JD	NOUNIPROTAC	Agonist	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7106).
• [2] Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol. 2009 Jul;14(3):328-37.
• [3] Reduced inhibition of cortical glutamate and GABA release by halothane in mice lacking the K+ channel, TREK-1. Br J Pharmacol. 2007 Nov;152(6):939-45.
• [4] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [5] Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat. 2007 Aug;3(4):441-453.
• [6] Effects of sevoflurane on carrageenan- and fentanyl-induced pain hypersensitivity in Sprague-Dawley rats. Can J Anaesth. 2009 Feb;56(2):126-35.
• [7] Enflurane directly depresses glutamate AMPA and NMDA currents in mouse spinal cord motor neurons independent of actions on GABAA or glycine receptors. Anesthesiology. 2000 Oct;93(4):1075-84.
• [8] Transmembrane residues define the action of isoflurane at the GABAA receptor alpha-3 subunit. Brain Res. 2005 Jan 25;1032(1-2):30-5.
• [9] Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups. Psychopharmacology (Berl). 2009 May;204(1):61-71.
• [10] GABA(A) receptor ligands and their therapeutic potentials. Curr Top Med Chem. 2002 Aug;2(8):817-32.
• [11] Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97.
• [12] Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79.